Spectral AI Inc Dossier
Qualitative Analysis
Business overview
Spectral AI, Inc. (NASDAQ: MDAI) is a Dallas-based predictive artificial intelligence company specializing in medical diagnostics for wound care. The company's core technology is the DeepView Wound Diagnostics System, a predictive diagnostic platform that combines proprietary deep-learning AI algorithms with multi-spectral imaging (MSI). DeepView extracts millions of pixels of data to distinguish between fully damaged, partially damaged, and healthy tissue characteristics invisible to the naked eye. This provides clinicians with an objective, immediate binary assessment of a wound's healing potential (such as burn wounds and diabetic foot ulcers) prior to treatment, significantly improving clinical outcomes and reducing healthcare costs.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Initiating commercial distribution of the FDA-cleared DeepView System for Burn Indication in the United States and preparing for international sales in the UK, Australia, and the GCC by late 2026.
Expected impact: Establishes the company's first commercial product footprint and shifts the business model toward commercial sales and licensing.
Developing advanced features for the DeepView System, including total body surface area mapping and rapid analysis capabilities, to address routine care and national emergency preparedness.
Expected impact: Enhances the clinical utility and competitive barriers of the DeepView platform.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides non-dilutive funding to support the clinical development, feature enhancement, and initial procurement of the DeepView System.
Terms: Total committed BARDA support of $86.6 million under an active contract valued up to $150.0 million, including a $31.7 million advanced funding award in March 2026.